Provider Selection In Small And Emerging Pharma Companies

Source: ISR Reports
Rebecca McAvoy_450x300
Rebecca McAvoy

As anyone who has ever attempted to sell clinical development services to pharma organizations can tell you, the task is no mean feat. It is difficult to determine who makes the decisions and who the influencers are. The presence of preferred provider agreements makes it tricky for a new provider to get its proverbial foot in the door. And, of course, every company has a different process for outsourcing clinical development work.

Small and emerging pharma companies have been a hot topic in the clinical development space for a while now. It seems like everyone in the industry wants a piece of them and wants to better understand how they operate. Industry Standard Research (ISR) has performed several market research studies over the past year that allow us to shed some light on what makes small and emerging pharma companies (those spending less than $100M annually on R&D) and their service provider selection processes different from larger competitors.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader